Main Article Content
Abstract
Background: Chronic low-grade inflammation is increasingly implicated in diabetic peripheral neuropathy (DPN). Tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) have been proposed as circulating correlates of nerve injury, yet the evidence is inconsistent, a previous synthesis addressed TNF-α alone, and no pooled estimate has ever been reported for IL-6.
Objective: To determine whether circulating TNF-α and IL-6 concentrations differ between diabetic patients with and without peripheral neuropathy, and to quantify the magnitude, precision, and consistency of any difference.
Methods: Four databases were searched for observational studies reporting serum or plasma TNF-α and/or IL-6 in diabetic patients with versus without neuropathy. Standardised mean differences (SMD, Hedges g) were pooled using a random-effects model, with Hartung–Knapp adjustment, restricted maximum-likelihood re-estimation, cluster-collapsed and leave-one-out analyses, and a prediction interval. Risk of bias used the Newcastle–Ottawa Scale and certainty the GRADE framework.
Results: Four studies (476 participants; 249 with DPN, 227 without) provided seven cytokine comparisons. The overall SMD was 0.70 (95% CI 0.22–1.18; p = 0.005; I² = 91%), robust across all sensitivity analyses. The effect was driven by IL-6, which was significantly and homogeneously elevated (SMD 0.65, 95% CI 0.42–0.87; I² = 2%). Pooled TNF-α was higher but non-significant and heterogeneous (SMD 0.71, 95% CI −0.18–1.60; I² = 95%), owing to one statin-treated cohort; excluding it raised the estimate to 0.88. Certainty was low for IL-6 and very low for TNF-α.
Conclusion: DPN is associated with higher circulating pro-inflammatory cytokines, with IL-6 the most consistent correlate and the first for which a pooled estimate is available. IL-6 merits prospective evaluation as a biomarker of neuropathy risk. Findings are hypothesis-generating.
Keywords
Article Details
Sriwijaya Journal of Neurology (SJN) allow the author(s) to hold the copyright without restrictions and allow the author(s) to retain publishing rights without restrictions, also the owner of the commercial rights to the article is the author.
